Welcome to our dedicated page for Opus Genetics SEC filings (Ticker: IRD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Opus Genetics, Inc. (Nasdaq: IRD) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other filings that document material events, financing transactions, and clinical or regulatory milestones. Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small-molecule therapies for other ophthalmic disorders, and its filings offer detailed insight into these activities.
Through its Form 8-K filings, the company reports material agreements and financings, such as securities purchase agreements for registered direct offerings of common stock and pre-funded warrants, including the use of proceeds to advance its LCA5 and BEST1 gene therapy clinical programs. These filings may also describe the terms of pre-funded warrants, closing conditions, and related legal opinions. Additional 8-Ks furnish press releases that announce financial results, cash position, and collaboration revenue, providing context on how Opus Genetics funds its research and development operations.
Regulation FD disclosures and other events reported in SEC filings frequently cover clinical and regulatory developments, including positive data from the OPGx-LCA5 Phase 1/2 trial, enrollment updates, and outcomes of FDA interactions such as Regenerative Medicine Advanced Therapy (RMAT) meetings. The company also uses 8-Ks to disclose inducement equity awards granted under its 2021 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
On Stock Titan, these filings are paired with AI-powered summaries that help explain the key points of each document, from financing structures to trial design details. Users can review Opus Genetics’ quarterly and annual reports when available, as well as current reports and exhibits, to better understand its ophthalmic gene therapy pipeline, collaboration arrangements, and capital structure as described in its official SEC submissions.
Nantahala Capital Management and its principals report a significant passive stake in Opus Genetics, Inc. As of December 31, 2025, they may be deemed to beneficially own 7,123,506 shares of common stock, representing 9.99% of the outstanding class.
This figure includes 2,342,176 shares that can be acquired within sixty days through warrant exercises. All voting and dispositive powers over the 7,123,506 shares are described as shared among Nantahala, Wilmot B. Harkey, and Daniel Mack, primarily through funds and separately managed accounts they oversee.
Blackwell Partners LLC - Series A, a fund advised by Nantahala, has the right to receive dividends or sale proceeds on more than five percent of the outstanding common stock. The reporting persons certify the holdings are in the ordinary course of business and not for changing or influencing control of Opus Genetics.
Opus Genetics, Inc. President and director Benjamin R. Yerxa reported an equity award in the form of 400,000 shares of common stock on January 22, 2026. The filing shows the shares at a price of $0 per share, reflecting a grant rather than an open-market purchase. Following this transaction, he beneficially owns 719,005 shares of common stock directly. According to the footnote, the award represents restricted stock units that vest in substantially equal quarterly installments on each anniversary of the grant date over the next sixteen quarters, conditioned on his continued service.
Opus Genetics, Inc. reported that its Chief Operating Officer, Joseph K. Schachle, received a grant of 250,000 shares of common stock in the form of restricted stock units on 01/22/2026. These RSUs vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen quarters, conditioned on his continuing service with the company. The grant was recorded at a price of $0 per share, reflecting that no cash payment is required from him for the award. Following this transaction, he beneficially owns 304,500 shares of Opus Genetics common stock, held directly.
Opus Genetics, Inc. granted 86,500 shares of its common stock in the form of restricted stock units to executive Amy Zaremba Rabourn, who serves as Head of Fin. Quality Assurance. The grant was made on January 22, 2026 at a price of $0 per share, reflecting an equity award rather than a market purchase.
The restricted stock units vest in substantially equal quarterly installments on each anniversary of the grant date over the next sixteen quarters, as long as she continues in service. After this grant, she beneficially owns 193,128 shares of common stock directly.
Opus Genetics, Inc. Chief Executive Officer and director Magrath George reported an equity award of company common stock. On January 22, 2026, he received 483,639 shares of common stock at a price of $0 per share, described as a grant of restricted stock units. After this grant, he beneficially owned 1,775,293 shares of Opus Genetics common stock in direct ownership.
The restricted stock units vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen quarters, and vesting is conditioned on his continuing service.
Opus Genetics, Inc. reported an equity award to its Chief Scientific & Dev. Officer, Jayagopal AshwathJanuary 22, 2026, he received 400,000 shares of common stock at a price of $0 per share, reported as a grant of restricted stock units. These RSUs vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen quarters, as long as he continues in service. Following this grant, he beneficially owns 525,807 shares of Opus Genetics common stock directly.
Opus Genetics, Inc. reported an equity award to its Chief Financial Officer, Robert E. Gagnon. On January 22, 2026, he received 400,000 shares of common stock at a price of $0 per share, reported as an acquisition. A footnote explains that this represents a grant of restricted stock units that vest in substantially equal quarterly installments on the anniversary of the grant date over the next 16 quarters, subject to his continuing service. Following this grant, Gagnon beneficially owned 600,000 shares of Opus Genetics common stock, held directly.
Opus Genetics, Inc. officer Amy Zaremba Rabourn, Head of Financial Quality Assurance, reported an automatic share withholding related to equity compensation. On January 18, 2026, 3,390 shares of common stock were withheld by the company at a value of $2.10 per share to cover tax obligations from the vesting and settlement of a restricted stock unit award. After this withholding, she beneficially owned 106,628 shares of Opus Genetics common stock directly. The footnote clarifies this was not an open market sale of securities but a tax-related withholding by the issuer.
Opus Genetics, Inc. officer Amy Zaremba Rabourn, Head of Fin. Quality Assurance, reported a share withholding related to equity compensation. On 01/10/2026, the issuer withheld 3,950 shares of common stock at $1.93 per share to cover tax obligations from the vesting and settlement of a restricted stock unit award. This was not an open market sale of securities, but an administrative tax withholding. After this transaction, Rabourn beneficially owned 110,018 shares of Opus Genetics common stock, held directly.
Opus Genetics, Inc. is highlighting its business at the 44th Annual J.P. Morgan Healthcare Conference, where management will deliver a corporate presentation on January 15, 2026 at 8:15 a.m. Pacific Time. A live webcast of the talk will be available through the company’s investor relations website, allowing investors to listen remotely. The associated January 2026 corporate presentation is provided as Exhibit 99.1 and is also posted in the “Overview” section of the company’s investor site.
FAQ
What is the current stock price of Opus Genetics (IRD)?
What is the market cap of Opus Genetics (IRD)?
